search
Back to results

A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Telmisartan 80 mg + hydrochlorothiazide 12.5 mg
Amlodipine 10 mg + hydrochlorothiazide 12.5 mg
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria: aged at least 60 years old mean SBP greater than 140 mmHg and mean DBP less than or equal to 95 mmHg 24-hour mean ambulatory SBP greater than 125 mmHg hypertensive patients not on current antihypertensive therapy or able to stop their current treatment for a period of up to eighteen weeks willing and able to provide written informed consent Exclusion criteria: women of child-bearing potential who are NOT practicing acceptable means of birth control known or suspected secondary hypertension mean SBP equal to or greater than 200 mmHg hepatic and/or renal dysfunction as defined by the following laboratory parameters: bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, patients post-renal transplant or with only one functioning kidney clinically relevant hypokalemia or hyperkalemia uncorrected volume or sodium depletion primary aldosteronism hereditary fructose intolerance biliary obstructive disorders patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin-II receptor antagonists history of drug or alcohol dependency within the previous six months chronic administration of any medication known to affect blood pressure, other than the trial medication concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing the consent form. symptomatic congestive heart failure (New York Heart Academy (NYHA) functional class CHF II-IV) unstable angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery less than three months prior to informed consent stroke less than six months prior to informed consent sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant arrhythmias as determined by the investigator hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for the previous three months night-shift workers who routinely sleep during the daytime and whose working hours include midnight to 4:00 AM known allergic hypersensitivity to any component of the formulations under investigation concomitant therapy with lithium, cholestyramine or colestipol resins. non-compliance with study medication (defined as less than 80% or more than 120%) during the run-in period current treatment with any antihypertensive agent any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan, amlodipine or hydrochlorothiazide

Sites / Locations

  • A.C.Z. Antwerpen/Stuyvenberg
  • Boehringer Ingelheim Investigational Site
  • A.Z. VUB
  • C.H.U. Liège (Ourthe-Amblève)
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Diacor
  • Kiljava Medical Research
  • Hämeenlinnan lääkäriasema Oy, Linnan klinikka
  • Boehringer Ingelheim Investigational Site
  • Kouvolan lääkäriasema
  • Hatanpään terveyskeskussairaala
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Hôpital de la Timone
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Deutsche Klinik für Diagnostik GmbH
  • Evangelisches Krankenhaus
  • 19 Redwood View
  • Adelaide and Meath Hospitals (incorrporating NCH)
  • Boehringer Ingelheim Investigational Site
  • Cardioperfect Research Room
  • Beaumont Park Clinic
  • Boehringer Ingelheim Investigational Site
  • Ospedale S. Luigi - S. Currò
  • Università di Ferrara
  • Az. Osped. Universitaria "Osp. Riuniti"
  • Azienda Ospedaliera "Maggiore della Carità"
  • Ospedale Scillesi d'America
  • Ospedale Civile
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Boehringer Ingelheim Investigational Site
  • Avda. Menendez Pidal, s&n
  • Hospital Gral de Jerez de la Frontera
  • Cardiology Service

Outcomes

Primary Outcome Measures

Change from baseline in the last 6-hour mean (relative to dose time) in SBP as measured by 24-hour ABPM at the end-of-study visit

Secondary Outcome Measures

Change from baseline in DBP in the last six hours of the 24-hour dose period
Change from baseline in pulse pressure (PP) in the last six hours of the 24-hour dose period
Change from baseline SBP and DBP for other time intervals ( i.e. 24-hour mean, morning mean (06:00-11:59), daytime mean (06:00-21:59), and night-time mean (22:00-05:59))
Change from baseline in patient HRQL as measured by the Psychological General Well-Being (PGWB) index.
Change from baseline in SBP in the last six hours of the 24-hour dose period (as measured by 24-hour ABPM).
Proportion of patients achieving a target response in SBP
Proportion of patients achieving SBP control
Proportion of patients achieving normal blood pressure
Proportion of patients achieving high-normal blood pressure
Change from baseline in trough seated SBP
Change from baseline in trough seated DBP
Safety and tolerability of the combination of telmisartan 80 mg and HCTZ 12.5 mg compared with amlodipine 10 mg and HCTZ 12.5 mg

Full Information

First Posted
October 14, 2005
Last Updated
October 31, 2013
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT00240474
Brief Title
A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)
Official Title
A Comparison of Telmisartan 80 mg + Hydrochlorothiazide 12.5 mg With Amlodipine 10 mg + Hydrochlorothiazide 12.5 mg in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension. A Prospective, Randomised, Open-label, Blinded End-point Evaluation. (ATHOS Study)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2013
Overall Recruitment Status
Completed
Study Start Date
December 2002 (undefined)
Primary Completion Date
March 2004 (Actual)
Study Completion Date
March 2004 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
The primary objective of this study was test non-inferiority of telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg in comparison to amlodipine 10 mg + HCTZ 12.5 mg in reducing ambulatory systolic blood pressure (SBP) in the last 6 hours of the 24-hour dosing interval (determined by ambulatory blood pressure monitoring: ABPM) in elderly patients with predominantly systolic hypertension.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1000 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Telmisartan 80 mg + hydrochlorothiazide 12.5 mg
Intervention Type
Drug
Intervention Name(s)
Amlodipine 10 mg + hydrochlorothiazide 12.5 mg
Primary Outcome Measure Information:
Title
Change from baseline in the last 6-hour mean (relative to dose time) in SBP as measured by 24-hour ABPM at the end-of-study visit
Time Frame
14 weeks
Secondary Outcome Measure Information:
Title
Change from baseline in DBP in the last six hours of the 24-hour dose period
Time Frame
week 8 and 14
Title
Change from baseline in pulse pressure (PP) in the last six hours of the 24-hour dose period
Time Frame
week 8 and 14
Title
Change from baseline SBP and DBP for other time intervals ( i.e. 24-hour mean, morning mean (06:00-11:59), daytime mean (06:00-21:59), and night-time mean (22:00-05:59))
Time Frame
week 8 and 14
Title
Change from baseline in patient HRQL as measured by the Psychological General Well-Being (PGWB) index.
Time Frame
week 8 and 14
Title
Change from baseline in SBP in the last six hours of the 24-hour dose period (as measured by 24-hour ABPM).
Time Frame
8 weeks
Title
Proportion of patients achieving a target response in SBP
Time Frame
14 weeks
Title
Proportion of patients achieving SBP control
Time Frame
14 weeks
Title
Proportion of patients achieving normal blood pressure
Time Frame
14 weeks
Title
Proportion of patients achieving high-normal blood pressure
Time Frame
14 weeks
Title
Change from baseline in trough seated SBP
Time Frame
14 weeks
Title
Change from baseline in trough seated DBP
Time Frame
14 weeks
Title
Safety and tolerability of the combination of telmisartan 80 mg and HCTZ 12.5 mg compared with amlodipine 10 mg and HCTZ 12.5 mg
Time Frame
14 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: aged at least 60 years old mean SBP greater than 140 mmHg and mean DBP less than or equal to 95 mmHg 24-hour mean ambulatory SBP greater than 125 mmHg hypertensive patients not on current antihypertensive therapy or able to stop their current treatment for a period of up to eighteen weeks willing and able to provide written informed consent Exclusion criteria: women of child-bearing potential who are NOT practicing acceptable means of birth control known or suspected secondary hypertension mean SBP equal to or greater than 200 mmHg hepatic and/or renal dysfunction as defined by the following laboratory parameters: bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, patients post-renal transplant or with only one functioning kidney clinically relevant hypokalemia or hyperkalemia uncorrected volume or sodium depletion primary aldosteronism hereditary fructose intolerance biliary obstructive disorders patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin-II receptor antagonists history of drug or alcohol dependency within the previous six months chronic administration of any medication known to affect blood pressure, other than the trial medication concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing the consent form. symptomatic congestive heart failure (New York Heart Academy (NYHA) functional class CHF II-IV) unstable angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery less than three months prior to informed consent stroke less than six months prior to informed consent sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant arrhythmias as determined by the investigator hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for the previous three months night-shift workers who routinely sleep during the daytime and whose working hours include midnight to 4:00 AM known allergic hypersensitivity to any component of the formulations under investigation concomitant therapy with lithium, cholestyramine or colestipol resins. non-compliance with study medication (defined as less than 80% or more than 120%) during the run-in period current treatment with any antihypertensive agent any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan, amlodipine or hydrochlorothiazide
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim Study Coordinator
Organizational Affiliation
BIL UK / Ireland
Official's Role
Study Chair
Facility Information:
Facility Name
A.C.Z. Antwerpen/Stuyvenberg
City
Antwerpen
ZIP/Postal Code
2060
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Aywaille
ZIP/Postal Code
4920
Country
Belgium
Facility Name
A.Z. VUB
City
Brussels
ZIP/Postal Code
1090
Country
Belgium
Facility Name
C.H.U. Liège (Ourthe-Amblève)
City
Esneux
ZIP/Postal Code
4130
Country
Belgium
Facility Name
Boehringer Ingelheim Investigational Site
City
Christianfeld
ZIP/Postal Code
DK-6070
Country
Denmark
Facility Name
Boehringer Ingelheim Investigational Site
City
Haderslev
ZIP/Postal Code
DK-6100
Country
Denmark
Facility Name
Boehringer Ingelheim Investigational Site
City
Herning
ZIP/Postal Code
DK-7400
Country
Denmark
Facility Name
Boehringer Ingelheim Investigational Site
City
Hvidovre
ZIP/Postal Code
DK-2650
Country
Denmark
Facility Name
Boehringer Ingelheim Investigational Site
City
Odder
ZIP/Postal Code
8300
Country
Denmark
Facility Name
Boehringer Ingelheim Investigational Site
City
Rødovre
ZIP/Postal Code
DK-2610
Country
Denmark
Facility Name
Boehringer Ingelheim Investigational Site
City
Vildberg
ZIP/Postal Code
DK-7480
Country
Denmark
Facility Name
Boehringer Ingelheim Investigational Site
City
Vildbjerg
ZIP/Postal Code
DK-7480
Country
Denmark
Facility Name
Boehringer Ingelheim Investigational Site
City
Vinderup
ZIP/Postal Code
DK-7830
Country
Denmark
Facility Name
Boehringer Ingelheim Investigational Site
City
Åbenrå
ZIP/Postal Code
DK-6200
Country
Denmark
Facility Name
Diacor
City
Helsinki
ZIP/Postal Code
FIN-00530
Country
Finland
Facility Name
Kiljava Medical Research
City
Hyvinkää
ZIP/Postal Code
FIN-05800
Country
Finland
Facility Name
Hämeenlinnan lääkäriasema Oy, Linnan klinikka
City
Hämeenlinna
ZIP/Postal Code
FIN-13100
Country
Finland
Facility Name
Boehringer Ingelheim Investigational Site
City
Jyväskylä
ZIP/Postal Code
FIN-40100
Country
Finland
Facility Name
Kouvolan lääkäriasema
City
Kouvola
ZIP/Postal Code
FIN-45100
Country
Finland
Facility Name
Hatanpään terveyskeskussairaala
City
Tampere
ZIP/Postal Code
FIN-33100
Country
Finland
Facility Name
Boehringer Ingelheim Investigational Site
City
Angers
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Ay
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Château Gontier Bazougues
ZIP/Postal Code
53200
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Jarny
ZIP/Postal Code
54800
Country
France
Facility Name
Hôpital de la Timone
City
Marseille cedex 05
ZIP/Postal Code
13385
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Mayenne
ZIP/Postal Code
53100
Country
France
Facility Name
Boehringer Ingelheim Investigational Site
City
Berlin
ZIP/Postal Code
12459
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Berlin
ZIP/Postal Code
13051
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Ellefeld
ZIP/Postal Code
08236
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Esslingen
ZIP/Postal Code
73733
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Flörsheim
ZIP/Postal Code
65439
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Hagen
ZIP/Postal Code
58091
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Hatten
ZIP/Postal Code
26209
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Kelkheim
ZIP/Postal Code
65779
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Leipzig
ZIP/Postal Code
04329
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Marl
ZIP/Postal Code
45772
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Münster
ZIP/Postal Code
48155
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Nürnberg
ZIP/Postal Code
90402
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Ornbau
ZIP/Postal Code
91737
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Rednitzhembach
ZIP/Postal Code
91126
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Riesa
ZIP/Postal Code
01589
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Rodgau-Dudenhofen
ZIP/Postal Code
63110
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Straßkirchen
ZIP/Postal Code
94342
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Wallerfing
ZIP/Postal Code
94574
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Werne
ZIP/Postal Code
59368
Country
Germany
Facility Name
Boehringer Ingelheim Investigational Site
City
Westerkappeln
ZIP/Postal Code
49492
Country
Germany
Facility Name
Deutsche Klinik für Diagnostik GmbH
City
Wiesbaden
ZIP/Postal Code
65191
Country
Germany
Facility Name
Evangelisches Krankenhaus
City
Witten
ZIP/Postal Code
58455
Country
Germany
Facility Name
19 Redwood View
City
Dublin
ZIP/Postal Code
24
Country
Ireland
Facility Name
Adelaide and Meath Hospitals (incorrporating NCH)
City
Dublin
ZIP/Postal Code
24
Country
Ireland
Facility Name
Boehringer Ingelheim Investigational Site
City
Dublin
ZIP/Postal Code
7
Country
Ireland
Facility Name
Cardioperfect Research Room
City
Dublin
ZIP/Postal Code
8
Country
Ireland
Facility Name
Beaumont Park Clinic
City
Dublin
ZIP/Postal Code
9
Country
Ireland
Facility Name
Boehringer Ingelheim Investigational Site
City
Kilkenny
Country
Ireland
Facility Name
Ospedale S. Luigi - S. Currò
City
Catania
ZIP/Postal Code
95100
Country
Italy
Facility Name
Università di Ferrara
City
Ferrara
ZIP/Postal Code
44100
Country
Italy
Facility Name
Az. Osped. Universitaria "Osp. Riuniti"
City
Foggia
Country
Italy
Facility Name
Azienda Ospedaliera "Maggiore della Carità"
City
Novara
ZIP/Postal Code
28100
Country
Italy
Facility Name
Ospedale Scillesi d'America
City
Scilla (rc)
ZIP/Postal Code
89058
Country
Italy
Facility Name
Ospedale Civile
City
Vittorio Veneto (TV)
ZIP/Postal Code
31029
Country
Italy
Facility Name
Boehringer Ingelheim Investigational Site
City
Beek en Donk
ZIP/Postal Code
5741 AR
Country
Netherlands
Facility Name
Boehringer Ingelheim Investigational Site
City
Den Haag
ZIP/Postal Code
2585 LJ
Country
Netherlands
Facility Name
Boehringer Ingelheim Investigational Site
City
Ewijk
ZIP/Postal Code
6644 CL
Country
Netherlands
Facility Name
Boehringer Ingelheim Investigational Site
City
Musselkanaal
Country
Netherlands
Facility Name
Boehringer Ingelheim Investigational Site
City
Oude Pekela
ZIP/Postal Code
9665 AR
Country
Netherlands
Facility Name
Boehringer Ingelheim Investigational Site
City
Rijswijk
ZIP/Postal Code
2281 AK
Country
Netherlands
Facility Name
Boehringer Ingelheim Investigational Site
City
Roelofarendsveen
ZIP/Postal Code
2371 RB
Country
Netherlands
Facility Name
Boehringer Ingelheim Investigational Site
City
Vaals
Country
Netherlands
Facility Name
Boehringer Ingelheim Investigational Site
City
Voerendaal
Country
Netherlands
Facility Name
Boehringer Ingelheim Investigational Site
City
Pretoria
ZIP/Postal Code
0038
Country
South Africa
Facility Name
Avda. Menendez Pidal, s&n
City
Cordoba
ZIP/Postal Code
14004
Country
Spain
Facility Name
Hospital Gral de Jerez de la Frontera
City
Jerez de la Frontera / Cádiz
ZIP/Postal Code
11407
Country
Spain
Facility Name
Cardiology Service
City
Santander
ZIP/Postal Code
39008
Country
Spain

12. IPD Sharing Statement

Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.400_U04-2006.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.400_literature.pdf
Description
Related Info

Learn more about this trial

A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)

We'll reach out to this number within 24 hrs